AbbVie, Roche drive Venclexta toward $3B with Rituxan combo nod in CLL

11th June 2018 Uncategorised 0

AbbVie and Roche’s blood cancer drug Venclexta just nabbed an FDA approval that spares certain relapsed leukemia patients chemotherapy—and could be key to $3 billion in peak sales to boot.

More: AbbVie, Roche drive Venclexta toward B with Rituxan combo nod in CLL
Source: fierce